

Annual General Meeting

22 November 2022

Disclaimer

The following provisions apply to this presentation. Please consider its contents carefully.

Currency of information

The information contained in this presentation is current as at the date of this presentation or such earlier date as specified in this presentation.

Summary information

The information in this presentation is of a general nature only. It does not purport to be complete.

Not investment advice

The information contained in this presentation is not investment or financial product advice or any recommendation to acquire or sell securities in McPherson's Limited (ASX: MCP). This presentation has been prepared without taking into account your investment objectives, financial situation or particular needs.

Company information

MCP's historical information in this presentation is, or is based on, information that has been released to ASX. This presentation should be read in conjunction with MCP's other periodic and continuous disclosure information lodged with ASX, which are available at <u>www.asx.com.au</u>.

Third party information

Certain market and industry data used in connection with this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither MCP nor any of its related bodies corporate, directors, employees, agents or advisers have independently verified such market or industry data and no representation or warranty is made as to the accuracy, completeness or reliability of the information.

Historical information

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as, and is not, an indication of future performance.

Forward looking information

This presentation contains certain forward-looking statements that involve risks and uncertainties many of which are beyond MCP's control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. MCP can give no assurance that these expectations will prove to be correct. You are cautioned not to place undue reliance on any forward-looking statements. Actual results may differ materially from those anticipated in these forward-looking statements due to many important factors, risks and uncertainties including, without limitation, risks associated with future capital needs, general economic uncertainty and other risks detailed from time to time in MCP's announcements to ASX. MCP does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect new information events or circumstances after the date of this presentation, except as may be required under applicable laws.

Disclaimer

No representation or warranty, whether express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. You should carry out your own investigations and analysis of MCP and verify the accuracy, reliability and completeness of the information contained in this presentation.

Neither MCP nor any of its related bodies corporate, directors, employees, agents and advisers accept any responsibility for any loss arising from anyone acting or refraining from acting in reliance on the contents of this presentation.

MCP AGM - 2022

 $M \subset P H E R S O N'S$

Health | Wellness | Beauty

2022 - McPherson's Annual General Meeting

Meeting Outline

O1 How to Vote

O2 Chairman's Address

O3 CEO & Managing Director's Address

O4 Formal Resolutions Business

05 Shareholder Questions

Our Speakers



ARI MERVIS Chairman



GRANT PECK CEO & Managing Director

ONLINE ATTENDEES – TEXT QUESTION PROCESS

Select the messaging tab and type your question in the Ask a question box.

Press the send arrow to submit your message for review.



Received

Your submitted questions along with any written responses from the meeting team can be found by selecting My Messages.

HOME MESSAGING		II. VOTING		
A Messaging				
Ask a question			>	
			0 / 1000	
		ALL MESSAGES	MY MESSAGES	
Moderator February 8, 2022 10:39 Ai	м			

Welcome to the meeting. If you would like to submit a question, type your question in the box above and then press the send arrow. Please include the number of the resolution at the beginning of your question. Questions may be moderated or amalgamated if there are multiple questions on the same topic.



ONLINE ATTENDEES – TEXT QUESTION PROCESS

Select the messaging tab, select the category your question relates to and type your question in the Ask a question box.



Press the send arrow to submit your message for review.

sage ior

Received

Your submitted questions along with any written responses from the meeting team can be found by selecting My Messages.

	j	II. VOTING		
•				
		>		
		0 / 1000		
	ALL MESSAGES	MY MESSAGES		
	MESSAGING	MESSAGING		

Welcome to the meeting. If you would like to submit a question, type your question in the box above and then press the send button. Questions may be moderated or amalgamated if there are multiple questions on the same topic.




ONLINE ATTENDEES – AUDIO QUESTION PROCESS

Click on the REQUEST TO SPEAK button at the bottom of the broadcast window. The meeting broadcast will be replaced with the audio questions interface.

Confirm your name, enter the topic of your question and click Submit Request.

Follow the instructions to grant access to your microphone and join the queue.





ONLINE ATTENDEES – AUDIO QUESTION PROCESS

Click on the REQUEST TO SPEAK button at the bottom of the broadcast window. The meeting broadcast will be replaced with the audio questions interface.

Confirm your name, enter the topic of your question and click **Submit Request**.

Follow the instructions to grant access to your microphone and join the queue.

Sroadcast

AUDIO QUESTIONS

To join the live audio questions queue, fill out the form below and click "Submit Request"

Your Name:

enter your name...

Your Topic or Question:

Enter the topic or resolution your question is related to...

Submit Request

RETURN TO BROADCAST





ONLINE ATTENDEES – VOTING


When open, the vote will be accessible by selecting the voting tab at the top of the screen.



To vote simply select the direction in which you would like to cast your vote. The selected option will change colour.



There is no submit or send button, your selection is automatically recorded. You can change your mind or cancel your vote any time before the poll is closed.







IN ROOM ATTENDEES – VOTING PROCESS

When voting opens, use the scroll wheel to highlight the resolution you wish to vote on then press

Once you have read the resolution,


press

LUMI

POWERED BY

to see the voting options.

Press 1 to vote FOR, 2 to vote AGAINST or 3 to ABSTAIN.







Chairman's Address

2022 - McPherson's Annual General Meeting

Est. 1860




CEO & Managing Director's Address

2022 - McPherson's Annual General Meeting

Est. 1860

Our People & Purpose

"To provide care solutions to nurture confident, healthy, and sustainable lifestyles"



FY22 Overview



\$214m TOTAL SALES REVENUE ▲ 7% on FY21:

\$200.5m

▲ 11% SALES GROWTH OF CORE **OWNED BRANDS**

\$11.8m \$10.7m UNDERLYING EBIT UNDERLYING PBT ▲ 9% **▲ 11%** on FY21: \$10.8m on FY21: \$9.6m

1% **GEARING FY21: 6.8%** 2.0 CPS

DIVIDEND FY21: 1.5 cps

FY22 Summary

- Sales up 7%, in line with stated guidance, driven by strong growth in six core owned brands and full year contribution from health business
- Strong underlying PBT despite cost pressures
- Underlying PBT impacted by commodity and sea freight cost increases
- Strong balance sheet with net debt of \$1.7m and gearing of 1%
- Cashflow conversion of **131%**
- Declared final **dividend of 2.0 cps** (FY21: 1.5 cps)



Innovation and New Products



FY22 Overview



\$214m TOTAL SALES REVENUE ▲ 7% on FY21:

\$200.5m

▲ 11% SALES GROWTH OF CORE **OWNED BRANDS**

\$11.8m \$10.7m UNDERLYING EBIT UNDERLYING PBT ▲ 9% **▲ 11%** on FY21: \$10.8m on FY21: \$9.6m

1% **GEARING FY21: 6.8%** 2.0 CPS

DIVIDEND FY21: 1.5 cps

FY22 Summary

- Sales up 7%, in line with stated guidance, driven by strong growth in six core owned brands and full year contribution from health business
- Strong underlying PBT despite cost pressures
- Underlying PBT impacted by commodity and sea freight cost increases
- Strong balance sheet with net debt of \$1.7m and gearing of 1%
- Cashflow conversion of **131%**
- Declared final **dividend of 2.0 cps** (FY21: 1.5 cps)

Refinement Reset year created a platform for growth Cross **business** Supply New Growing stability Price **Strategic** alignment Continued leadership, Ranging with increases Alliance provides and innovation increments winning structure, implemented with strong resource business and focus driving brand customers in inflationary Chemist growth leverage performance on NPD processes in environment Warehouse opportunity between and focus partnership in Health **Health and Beauty** 0

Key Achievements and Strategy

Sustainability



Achieve Net Zero by 2035 across our scope 1,2 and 3 emissions.

Sustainable Development Goals





Implement a Sustainable Supply Chain Policy

Sustainable Development Goals





Achieve the APCO Sustainable Packaging Goals by 2025 across our core brands.

Sustainable Development Goals





Implement guidelines by the end of 2022

FY23 so far

- Continued strength in pharmacy in Q1'23 with strong brands and strategic alliances
- Investment against growth brands (Manicare and Lady Jayne) and expansion brand (Fusion)
- Grocery channel impacted by weaker consumer confidence and margins impacted by increased costs
- Observing moderation in costs but will take time to work through supply chain
- Continue to take pricing actions to protect margins
- Remain confident in resilience of pharmacy channel growth through brand,

customer and category expansion

Summary

- **Stabilised the business** in FY22 and returned to profitable underlying growth
- Chemist Warehouse Strategic Alliance to deliver future growth
- Revised our **Purpose and Values**
- Simplified and improved processes, refined strategy revealing more opportunities
- Brands and innovation to drive growth in Pharmacy sector
- Continued focus on **sustainability**



Formal Matters

- 1 Financial Statements and Reports
- 2 Remuneration Report
- 3 Election of a Director Helen Thornton
- 4 Approval of Performance Rights Managing Director

AGENDA ITEM 1: FINANCIAL STATEMENTS AND REPORTS

To consider the Financial Statements, the Directors'

Report and the Auditor's Report for the Company for

the year ended 30 June 2022

AGENDA ITEM 2: REMUNERATION REPORT

To adopt the Remuneration Report for the Company for the financial year ended 30 June 2022.

In accordance with the Corporations Act 2001 (Cth) (Corporations Act), this resolution is advisory only and does not bind the Company or the directors of the Company (Directors). The Directors will consider the outcome of the vote and comments made by securityholders on the remuneration report at the meeting when reviewing the Company's remuneration policies

AGENDA ITEM 2: PROXY VOTES

	PROXY VOTES RECEIVED (MILLIONS)					
	500					
ITEM 2	FOR	FOR	AGAINST	AGAINST	OPEN	OPEN
	NO.	%	NO.	%	NO.	%
REMUNERATION REPORT	70.0	86.7	9.8	12.1	1.0	1.2

AGENDA ITEM 3: ELECTION OF A DIRECTOR MS. HELEN THORNTON



To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"To elect as a director of the Company, Ms. Helen Thornton, who having been appointed a director of MCP on 20 December 2021 in accordance with the Company's Constitution, offers herself for election as a director of MCP."

Relevant information about Ms. Thornton is set out in the Explanatory Notes to the Notice of Annual General Meeting.

AGENDA ITEM 3: PROXY VOTES

	PROXY VOTES RECEIVED (MILLIONS)						
ITEM 2	FOR	FOR	AGAINST	AGAINST	OPEN	OPEN	
	NO.	%	NO.	%	NO.	%	
ELECT HELEN THORNTON	79.3	97.6	0.8	1.0	1.1	1.4	

AGENDA ITEM 4: APPROVAL OF THE ISSUE OF PERFORMANCE RIGHTS TO THE MANAGING DIRECTOR, UNDER THE PERFORMANCE RIGHTS PLAN

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That for the purposes of Part 2E.1 of the Corporations Act and ASX Listing Rule 10.14, and for all other purposes, the grant of performance rights and shares on exercise of such performance rights to Mr. Grant Peck, the Managing Director of the Company, under the McPherson's Limited Performance Rights Plan and his employment agreement with the Company, is approved on the terms set out in the Explanatory Notes to the Notice of Annual General Meeting."

AGENDA ITEM 4: PROXY VOTES

	PROXY VOTES RECEIVED (MILLIONS)						
ITEM 2	FOR	FOR	AGAINST	AGAINST	OPEN	OPEN	
	NO.	%	NO.	%	NO.	%	
APPROVAL OF ISSUE OF							
PERFORMANCE RIGHTS – MD	75.7	93.5	4.3	5.3	1.0	1.2	





Health | Wellness | Beauty





2022 - McPherson's Annual General Meeting